What Should Investors Know About The Future Of Koninklijke DSM N.V.’s (AMS:DSM)?

Simply Wall St
January 25, 2019

In September 2018, Koninklijke DSM N.V. (AMS:DSM) released its earnings update. Generally,
analyst consensus outlook appear
bearish,
with earnings expected to decline by -13% in the upcoming year
relative to
the past 5-year average growth rate of 54%.
With trailing-twelve-month net income at current levels of €1.8b, the consensus growth rate suggests that earnings will decline to
€1.5b by 2020.
Below is a brief commentary on the longer term outlook the market has for Koninklijke DSM.
Readers that are interested in understanding the company beyond these figures should
research its fundamentals here.

Exciting times ahead?

Longer term expectations from the 23 analysts covering DSM’s stock is one of
positive
sentiment.
Given that it becomes hard to forecast far into the future, broker analysts tend to project ahead roughly three years.
I’ve plotted out each year’s earnings expectations and inserted a line of best fit to calculate an annual growth rate from the slope in order to understand the overall trajectory of DSM’s earnings growth over these next few years.

ENXTAM:DSM Future Profit January 25th 19

From the current net income level of €1.8b and the final forecast of €1.8b by 2022, the annual rate of growth for DSM’s earnings is 0.4%.
However, if we exclude extraordinary items from net income, we see that earnings is projected to fall over time, resulting in an EPS of €6.03 in the final year of forecast compared to the current
€10.07 EPS today.
Analysts are predicting this high revenue growth to squeeze profit margins over time, from 20% to 19% by the end of 2022.

Next Steps:

Future outlook is only one aspect when you’re building an investment case for a stock. For Koninklijke DSM,
I’ve put together
three
relevant
factors
you should
further examine:

Valuation: What is Koninklijke DSM worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether Koninklijke DSM is currently mispriced by the market.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.

Simply Wall St is a financial technology startup focused on providing unbiased, high-quality research coverage on every listed company in the world. Our research team consists of equity analysts with a public, market-beating track record. Learn more about the team behind Simply Wall St.

DSM’s investment overview

DSM’s Competitors

About Us

Become a better investor Simply Wall St is an award winning start-up aiming to replace human stockbrokers by providing you with high quality financial data and analysis presented in a beautiful visual way everybody can understand, at a fraction of the cost (try our FREE plan).

Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us. Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927).